The regulation of noncancer toxicants, including neurotoxicants, has usually been based upon a reference dose (allowable daily intake). A reference dose is obtained by dividing a no-observed-effect level by uncertainty (safety) factors to account for intraspecies and interspecies sensitivities to a chemical. It is assumed that the risk at the reference dose is negligible, but no attempt generally is made to estimate the risk at the reference dose. A procedure is outlined that provides estimates of risk as a function of dose. The first step is to establish a mathematical relationship between a biological effect and the dose of a chemical. Knowledge of biological mechanisms and/or pharmacokinetics can assist in the choice of plausible mathematical models. The mathematical model provides estimates of average responses as a function of dose. Secondly, estimates of risk require selection of a distribution of individual responses about the average response given by the mathematical model. In the case of a normal or lognormal distribution, only an estimate of the standard deviation is needed. The third step is to define an adverse level for a response so that the probability (risk) of exceeding that level can be estimated as a function of dose. Because a firm response level often cannot be established at which adverse biological effects occur, it may be necessary to at least establish an abnormal response level that only a small proportion of individuals would exceed in an unexposed group. That is, if a normal range of responses can be established, then the probability (risk) of abnormal responses can be estimated.(ABSTRACT TRUNCATED AT 250 WORDS)
[1]
R L Kodell,et al.
Upper confidence limits on excess risk for quantitative responses.
,
1993,
Risk analysis : an official publication of the Society for Risk Analysis.
[2]
D W Gaylor,et al.
Incidence of developmental defects at the no observed adverse effect level (NOAEL).
,
1992,
Regulatory toxicology and pharmacology : RTP.
[3]
D. Barnes,et al.
Reference dose (RfD): description and use in health risk assessments.
,
1988,
Regulatory toxicology and pharmacology : RTP.
[4]
W. Slikker,et al.
Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA).
,
1988,
Toxicology and applied pharmacology.
[5]
D W Gaylor,et al.
Issues in qualitative and quantitative risk analysis for developmental toxicology.
,
1988,
Risk analysis : an official publication of the Society for Risk Analysis.
[6]
K S Crump,et al.
A new method for determining allowable daily intakes.
,
1984,
Fundamental and applied toxicology : official journal of the Society of Toxicology.
[7]
David W. Gaylor,et al.
Dose-response modeling of quantitative response data for risk assessment
,
1992
.
[8]
W Slikker,et al.
Risk assessment for neurotoxic effects.
,
1990,
Neurotoxicology.
[9]
W. Slikker,et al.
Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate.
,
1989,
Neurotoxicology.